Our study, published in Diabetes, shows that weight loss involves complex communication between the gut and liver, and understanding how these systems are affected by different weight-loss approaches can help us tailor specific interventions for patients. https://t.co/YH4sDX2wQX
A TRIUMPH for the GCGR-GLP1R-GIPR triple agonist Retatrutide in P3. Participants with #obesity and knee osteoarthritis taking retatrutide 12 mg lost an average of 28.7% of their body weight at 68 weeks. Mild dysesthesias noted #weightloss#arthritis https://t.co/Ne2TlqaYNU
Congratulations to the 2026 Laureate Award Recipients | We celebrate the highest achievements in endocrinology across research, clinical care, leadership, mentorship, innovation, and service. View the winners: https://t.co/boEvCw97LA #ENDO2026#endocrinology
Resolution of Metabolic Dysfunction-associated Steatohepatitis With No Worsening of Fibrosis After Bariatric Surgery Improves 15-year Survival: A Prospective Cohort Study - Clinical Gastroenterology and Hepatology #MASH#Obesity https://t.co/p5OFJzPh6R
My newest paper: Multiple data sets for semaglutide and MASH. Semaglutide may reverse the proteomic signature in people with MASH. No measurable GLP-1 receptor in the liver.
https://t.co/HR3JedpvOk
Thanks to the Endocrine Society for the invitation. Bariatric surgery is the most efficacious treatment for obesity. Because of the discontinuation rates of GLP-1RA and the increase in prevalence of Stage 3 obesity, I think bariatric surgery will continue to have a role.
🚨 GLP-1s vs Surgery: Who Wins Long Term?
- - -
A new 2-year comparative study from NYU Langone just dropped—and the results are clear:
📊 Bariatric Surgery vs GLP-1s (semaglutide/tirzepatide):
🔹 25.7% total body weight loss with surgery vs 5.3% with GLP-1s (intention-to-treat)
🔹 Even in per-protocol analysis (continuous GLP-1 use), surgery still outperformed: 24.6% vs 7.6%
🔹 Surgery had better HbA1c improvement, too
🔍 Translational Insight:
Yes, the relatively low weight loss in the medication group was partly due to therapy interruptions and discontinuation. But that’s exactly the point:
➡️ If a treatment is regularly interrupted by prior auths, high out-of-pocket costs, or drug shortages, that limits its real-world effectiveness.
➡️ Clinical effectiveness ≠ theoretical efficacy in a vacuum. Access matters.
📌 Bottom line:
For patients with severe obesity (BMI ≥35), bariatric surgery still provides superior long-term outcomes—and it does so reliably, without being derailed by market forces.
Abstract: https://t.co/NlOas6X8j6
ACS Clowes Award recipient Dr. Tammy Kindel is helping uncover significant extended benefits after bariatric surgery.
Her project focuses on understanding how bariatric surgery improves heart function in patients with obesity-related heart failure. https://t.co/5Xi7kS7z8p
.@UMichMedSchool professor Nadejda Bozadjieva Kramer has dedicated her career to studying obesity and metabolic dysfunction, conditions that disproportionately affect veterans and increase their risk of diabetes, heart disease and other chronic illnesses. https://t.co/kL2rTfmxCX
3 years of war in Ukraine.
Supporting Ukraine is not only a matter of solidarity, but also upholding the principles of sovereignty & territorial integrity.
We stand firm w/🇺🇦& its people, reaffirming that lasting and just peace based on int/ law will prevail.
#StandWithUkraine️
Any attempt to division of Europe weakens us. We need an EU response not because of the influence, but because of our founding principles. This can only happen with an immediate summit between the US, EU countries and allies, where all points of view are frankly put on the table.
Dr. Amy Rothberg, clinical professor and member of the Caswell Diabetes Institute, spoke to @washingtonpost about prescriptions for weight-loss drugs. https://t.co/3ovHsq97w3